Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): A balancing act

Abstract

Advances in highly active antiretroviral therapy (HAART) options for people living with HIV/AIDS have resulted in decreased morbidity and mortality. To some extent, the role of disease progression in eroding quality of life (QOL) erosion in the pre-HAART age is now supplanted by drug toxicities, one of the Achilles' heels of HAART. This article reviews research findings on treatment and QOL outcomes a decade into the HAART era. © The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.